The report
North American Drug Delivery Technologies Market (Metered Dose Inhalers,
Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches,
Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular
Implants) – Forecasts To 2017 by MarketsandMarkets is now available at
RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with North American Drug Delivery
Technologies Market (Metered Dose Inhalers, Needle-Free Injectors,
Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps,
Drug Eluting Stents, Sustained Release, Ocular Implants) – Forecasts To 2017 in
subject line and your contact details to purchase this report or get your
questions answered.
Patent
expiry of major blockbuster drugs is a prime concern for pharmaceutical
companies, as developing a new chemical entity (NCE) is more expensive and time
consuming than a novel drug delivery technology. Therefore, in recent years,
several pharmaceutical companies have employed drug delivery technology as a
life cycle management tool for some of their blockbuster drugs, the patents for
which are set to expire in the near future.
The North
American drug delivery market was estimated to be worth $66.7 billion in 2012,
and is expected to register a CAGR of 8.9% between 2012 and 2017. Based on the
route of administration, the drug delivery market has been classified as oral,
pulmonary, injectable, transdermal, implantable, ocular, nasal, transmucosal,
and topical. In 2012, oral drug delivery segment dominated the market with a
share of approximately 38%, followed by pulmonary drug delivery segment with a
20% share.
The drug
delivery technologies that have recently gained importance in the North
American market include orodispersible tablet (ODT), dry powder inhalers,
transdermal patches, needle-free injectors, auto and pen injectors, and buccal
transmucosal tablets; controlled release is the most widely accepted
technology. The use of implantable devices for drug delivery is also on a rise.
Big
pharmaceutical companies such as Pfizer and Merck have established in-house
capabilities for the development of drug delivery technologies. On the
contrary, many other companies are still relying on specialty companies engaged
in the development of drug delivery technologies. High level of competition and
increasing need for outsourcing has resulted in the drug delivery market to be
fragmented, with several small companies developing novel drug delivery
technologies for niche therapeutic applications.
The North
American drug delivery market is largely dominated by the U.S. (accounting for
about 89% of the overall market). The key drivers for the U.S. drug delivery
market are the well established pharmaceutical industry , healthcare reforms,
and favourable changes in the FDA review process. Factors such as low cost drug
manufacturing and rising number of drug delivery formulations and devices are
propelling the Canadian market.
Request a Sample Copy @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=105813
Key
players in the drug delivery technologies market are 3M Company (U.S.), Aptalis
Pharma, Inc. (U.S.), Baxter International, Inc. (U.S.), Becton, Dickinson &
Co. (U.S.), Catalent Pharma Solutions (U.S.), The Dow Chemical Company (U.S.),
Endo Pharmaceuticals (U.S.), Johnson & Johnson (U.S.), Nektar Therapeutics
(U.S.) and Valeant Pharmaceuticals (Canada).
Scope of the Report
This
research report categorizes and analyzes the North American Drug Delivery
Technologies market on the basis of routes of administration. These markets are
further divided into segments and sub-segments, to provide exhaustive value
analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is
comprehensively analyzed at a granular level by country (U.S and Canada), to
provide in-depth information on the North American market scenario.
North American drug delivery
technologies market, by segment:
Oral Drug
Delivery, Controlled Release, Orodispersible Tablets (ODT) and Taste Masking, Others,
Pulmonary Drug Delivery, Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers,
Transdermal Drug Delivery, Passive Drug Delivery, Reservoir System, Matrix
System, Active Drug Delivery, Iontophoresis, Microporation, Others, Injectable
Drug Delivery, Conventional Injection Devices, Fillable Syringes, Prefilled
Syringes, Self-injection Devices, Needle-free Injectors, Auto-injectors or
Safety Syringe Devices, Pen Injectors, Others, Ocular Drug Delivery, Eye Drops,
Ointment and Gel, Others, Nasal Drug Delivery, Nasal Drops, Nasal Sprays, Nasal
Inhalers, Others, Topical Drug Delivery, Liquid Formulations, Semisolid
Formulations, Solid Formulations, Implantable Drug Delivery, Drug-Eluting
Stents, Implantable Infusion Pumps, Contraceptive Implants, Intravitreal
Implants, Brachytherapy Seeds, Transmucosal Drug Delivery, Oral (Buccal and
Sublingual), Others (Rectal and Vaginal)
North America drug delivery
technologies market, by country:
U.S, Canada
Explore More Reports @ http://www.rnrmarketresearch.com/reports/life-sciences/healthcare/drug-delivery
Company Profiles (Overview,
Financials, Products & Services, Strategy, And Developments)
- 3M Company
- Aptalis Pharma, Inc.
- Baxter International, Inc.
- Becton, Dickinson And Company
- Catalent Pharma Solutions
- Cima Labs
- Endo Health Solutions, Inc.
- Johnson & Johnson, Inc.
- Nektar Therapeutics, Inc.
- Optinose As
- Psivida Corporation
- The Dow Chemical Company
- Valeant Pharmaceuticals
- 3M Company
- Aptalis Pharma, Inc.
- Baxter International, Inc.
- Becton, Dickinson And Company
- Catalent Pharma Solutions
- Cima Labs
- Endo Health Solutions, Inc.
- Johnson & Johnson, Inc.
- Nektar Therapeutics, Inc.
- Optinose As
- Psivida Corporation
- The Dow Chemical Company
- Valeant Pharmaceuticals
For
more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441
Website:
http://www.rnrmarketresearch.com
No comments:
Post a Comment
Note: only a member of this blog may post a comment.